PMID- 28428353
OWN - NLM
STAT- MEDLINE
DCOM- 20170622
LR  - 20190722
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Linking)
VI  - 63
IP  - 6
DP  - 2017 Jun
TI  - Development of a BNP1-32 Immunoassay That Does Not Cross-React with proBNP.
PG  - 1110-1117
LID - 10.1373/clinchem.2016.269712 [doi]
AB  - BACKGROUND: Plasma B-type natriuretic peptide (BNP) concentration reflects 
      cardiac dysfunction and assists in determining the diagnosis and prognosis of 
      heart failure (HF). Current BNP assays overestimate circulating bioactive BNP1-32 
      concentrations as they also detect less active BNP metabolites and proBNP. A 
      specific BNP1-32 assay with negligible cross-reactivity to proBNP and/or BNP 
      metabolites may be advantageous. METHODS: We developed a Luminex-based specific 
      BNP1-32 immunoassay and compared results obtained from 3 other BNP assays (a 
      Luminex-based total-BNP assay, our BNP RIA, and the commercially available Abbott 
      Architect BNP assay) in plasma from 42 patients with HF and 22 healthy controls. 
      RESULTS: The BNP1-32 assay showed 57% cross-reactivity with BNP2-32, but </=0.1% 
      cross-reactivity to BNP3-32, other BNP metabolites, and proBNP; its detection 
      limit was 0.35 ng/L; and intra- and interassay CVs were <15%. BNP 
      immunoreactivity increased with HF severity (median concentrations being 0.3, 
      0.8, 26.2, and 17.3 ng/L in healthy controls and 40.7, 139, 465, and 1778 ng/L in 
      HF patients for the BNP1-32, total-BNP, BNP RIA, and Abbott BNP assays 
      respectively). The fold increase between HF cases with the New York Heart 
      Association (NYHA) class IV was significantly greater with the BNP1-32 assay than 
      the Abbott BNP (P = 0.026) and the BNP RIA (P < 0.0001) but not the total-BNP 
      assay. CONCLUSIONS: We have developed the first assay that measures BNP1-32 in 
      plasma without interference by proBNP. Analysis of larger patient cohorts is now 
      required to compare the performance of this assay with current less specific 
      assays for the diagnosis or prognosis of HF.
CI  - (c) 2017 American Association for Clinical Chemistry.
FAU - Lewis, Lynley K
AU  - Lewis LK
AD  - Christchurch Heart Institute, Department of Medicine, University of Otago, 
      Christchurch, New Zealand; Lynley.lewis@otago.ac.nz.
FAU - Raudsepp, Sara D
AU  - Raudsepp SD
AD  - Christchurch Heart Institute, Department of Medicine, University of Otago, 
      Christchurch, New Zealand.
FAU - Yandle, Tim G
AU  - Yandle TG
AD  - Christchurch Heart Institute, Department of Medicine, University of Otago, 
      Christchurch, New Zealand.
FAU - Prickett, Timothy C
AU  - Prickett TC
AD  - Christchurch Heart Institute, Department of Medicine, University of Otago, 
      Christchurch, New Zealand.
FAU - Richards, A Mark
AU  - Richards AM
AD  - Christchurch Heart Institute, Department of Medicine, University of Otago, 
      Christchurch, New Zealand.
AD  - Cardiovascular Research Institute, National University Heart Centre, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20170420
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Cross Reactions/immunology
MH  - Female
MH  - Heart Failure/*blood/diagnosis
MH  - Humans
MH  - Immunoassay/*methods
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood/metabolism
EDAT- 2017/04/22 06:00
MHDA- 2017/06/24 06:00
CRDT- 2017/04/22 06:00
PHST- 2016/11/28 00:00 [received]
PHST- 2017/02/27 00:00 [accepted]
PHST- 2017/04/22 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
PHST- 2017/04/22 06:00 [entrez]
AID - clinchem.2016.269712 [pii]
AID - 10.1373/clinchem.2016.269712 [doi]
PST - ppublish
SO  - Clin Chem. 2017 Jun;63(6):1110-1117. doi: 10.1373/clinchem.2016.269712. Epub 2017 
      Apr 20.